Predicting and Preventing Ventilator-Induced Lung Injury
预测和预防呼吸机引起的肺损伤
基本信息
- 批准号:10318215
- 负责人:
- 金额:$ 56.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcute Respiratory Distress SyndromeAffectAlgorithmsAlveolarAlveolusAnimal ModelBiochemicalBiological MarkersCOVID-19CaringClinicalComplexComputer ModelsConflict (Psychology)DataFeedbackFunctional disorderFutureGasesHeterogeneityHospital MortalityHospitalsHuman ResourcesIndividualInflammationInflammatoryInjuryLeadLungLung ComplianceManualsMeasurementMeasuresMechanical ventilationMechanicsModelingMonitorMusOutcomePathogenesisPatientsPatternPeriodicityPersonsPharmacologyPhenotypePhysiologyPneumoniaProcessProtocols documentationProviderPulmonary EdemaResourcesRespiratory FailureRiskRisk FactorsRodentSafetySepsisStretchingStructureSystemTestingThinnessTimeTissuesTrainingTraumaUnited StatesVentilatorVentilator-induced lung injuryVolutraumaWorkloadatelectraumabasecostexperienceimprovedin silicoinnovationlung injurymathematical modelmechanical forcemortalitypandemic diseasepatient populationpatient variabilitypersonalized approachprediction algorithmpredictive modelingpressurepreventprocess repeatabilityprospectivepulmonary functionreal time modelresearch clinical testingrespiratoryresponsesimulationsurfactanttemporal measurementtoolventilation
项目摘要
Project Summary
Acute respiratory distress syndrome (ARDS) is a rapid onset respiratory failure that is caused by factors ranging
from pneumonia to sepsis. The impact of ARDS is substantial with more than 200,000 cases per year in the
United States and an estimated mortality rate of 40%. All ARDS patients are mechanically ventilated to overcome
the derangements in lung function caused by pulmonary edema, surfactant inactivation, and alveolar collapse.
However, this essential mechanical ventilation can cause additional ventilator-induced lung injured (VILI) through
tissue overdistension (volutrauma), the cyclic collapse and reopening of small airways and alveoli (atelectrauma),
and inflammatory effects (biotrauma). Since VILI is a risk in all ARDS patients, and a significant contributor to
ARDS mortality, improvements in ventilatory management are a key step in improving ARDS survival. However,
further refinement of ventilation protocols to reduce VILI is challenging because of differences between patients
and the changes in lung function that occur over time as ARDS worsens or resolves. Because of this inter- and
intra-patient variability, ventilation that is beneficial in one person can be harmful in another. To overcome this
challenge, we postulate that ventilation should be guided using a VILI cost function that provides real-time
feedback of ventilation safety by describing the amount of VILI that is occurring. Our study will define such VILI
cost functions based on the changes in lung function, structure, and inflammation that are the result of injurious
ventilation. Using the cost function as a guide, the optimally safe ventilation for each patient could be determined
by manually adjusting the ventilator settings. However, given the large number of permutations of ventilation
adjustments this is not a practical approach. Instead, we will develop a mathematical model to predict optimal
ventilation for each patient. These simulations will be personalized by fitting to real time pressure-flow
measurements and then used to find the ventilation pattern that minimizes the VILI Cost Function. The predicted
optimally safe ventilation will then be applied, and the process repeated to account for changes in lung function
over time. The potential benefits of the proposed study are substantial. The VILI cost functions we define will
provide an essential measurement of ventilation safety. Our innovative approach to optimize lung-protective
ventilation using predictive models may lead to decreased ARDS mortality by protecting the injured lung while,
at the same time, reducing provider workload. The proposed system also represents a paradigm shift in the way
that ventilation strategies are established. Instead of testing a strategy in animal models and then in the
heterogeneous ARDS patient population, where the effect may be beneficial to some patients and harmful to
others, focus may be directed towards identifying algorithms that predict and prevent VILI independent of ARDS
phenotype and lung mechanical function.
项目摘要
急性呼吸窘迫综合征(ARDS)是一种快速发作的呼吸衰竭,
从肺炎到败血症急性呼吸窘迫综合征的影响是巨大的,在美国每年有超过20万例病例。
美国,估计死亡率为40%。所有的ARDS患者都是机械通气,以克服
由肺水肿、表面活性剂失活和肺泡萎陷引起的肺功能紊乱。
然而,这种必要的机械通气可能会导致额外的呼吸机诱导的肺损伤(VILI),
组织过度膨胀(体积创伤),小气道和肺泡的周期性塌陷和重新开放(肺创伤不全),
和炎症效应(生物创伤)。由于VILI是所有ARDS患者的一种风险,并且是
提高ARDS死亡率,改善辅助治疗是提高ARDS生存率的关键。然而,在这方面,
由于患者之间的差异,进一步完善通气方案以减少VILI具有挑战性
以及随着时间的推移发生的肺功能的变化,如ARDS恶化或消退。由于这种内部和
患者内的可变性,对一个人有益的通气可能对另一个人有害。为了克服这个
挑战,我们假设应该使用VILI成本函数来指导通气,
通过描述发生的VILI的量来反馈通气安全性。我们的研究将定义这样的VILI
基于肺功能、结构和炎症的变化的成本函数,这些变化是损伤性肺损伤的结果。
通风.使用成本函数作为指导,可以确定每个患者的最佳安全通气
通过手动调节呼吸机设置。然而,考虑到通风的大量排列
这不是一个实际的办法。相反,我们将开发一个数学模型来预测最佳的
为每一位患者提供治疗。这些模拟将通过拟合真实的时间压力-流量来个性化
测量,然后用于找到使VILI成本函数最小化的通风模式。预测
然后应用最佳安全通气,并重复该过程以考虑肺功能的变化
随着时间拟议研究的潜在益处是巨大的。我们定义的VILI成本函数将
提供通风安全的基本测量。我们的创新方法,以优化肺部保护
使用预测模型的通气可以通过保护受伤的肺而导致降低的ARDS死亡率,
同时,减少供应商的工作量。拟议的系统也代表了一种范式转变,
建立通风策略。而不是在动物模型中测试策略,然后在
异质性ARDS患者人群,其中效果可能对某些患者有益,对某些患者有害。
其他人,焦点可能指向识别预测和预防独立于ARDS的VILI的算法
表型和肺机械功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bradford J Smith其他文献
Bradford J Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bradford J Smith', 18)}}的其他基金
Predicting and Preventing Ventilator-Induced Lung Injury
预测和预防呼吸机引起的肺损伤
- 批准号:
10543770 - 财政年份:2021
- 资助金额:
$ 56.59万 - 项目类别:
The Importance of Inhomogeneity in the Pathogenesis of Lung Injury
不均匀性在肺损伤发病机制中的重要性
- 批准号:
9377181 - 财政年份:2017
- 资助金额:
$ 56.59万 - 项目类别:
The Importance of Inhomogeneity in the Pathogenesis of Lung Injury
不均匀性在肺损伤发病机制中的重要性
- 批准号:
9111072 - 财政年份:2015
- 资助金额:
$ 56.59万 - 项目类别:
The Importance of Inhomogeneity in the Pathogenesis of Lung Injury
不均匀性在肺损伤发病机制中的重要性
- 批准号:
8949132 - 财政年份:2015
- 资助金额:
$ 56.59万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 56.59万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 56.59万 - 项目类别:














{{item.name}}会员




